FDA approves Korlym (Corcept Therapeutics) for Cushings Syndrome

The FDA has approved Korlym (mifepristone)(formerly Corlux) from Corcept Therapeutics to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing�s syndrome. This drug was approved for use in patients with endogenous Cushing�s syndrome who have Type 2 Diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used (contraindicated) by pregnant women. Prior to FDA�s approval of Korlym, there were no approved medical therapies for the treatment of endogenous Cushing�s syndrome. Mifepristone already is marketed in the US under the name Mifeprex by Danco Laboratories as a drug to induce abortions in the first 49 days of pregnancy.